SCHEMBL639417

SCHEMBL639417

Nc1nc(NC2O[C@H](CO)[C@@H](O)[C@H]2OP(=O)(O)O)nc(O)c1N

nearest known ligand 0.44

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.42
ADK P55263 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL769262 0.77 ADORA1 (0.45) ADORA1
SCHEMBL5916326 0.71 ADORA1 (0.38) ADORA1
SCHEMBL783243 0.69 LGALS8 (0.41) ADORA1
SCHEMBL5245060 0.69 ADORA1 (0.38) ADORA1
SCHEMBL574712 0.69 ADORA1 (0.39) ADORA1
SCHEMBL263892 0.68 ADORA1 (0.41) ADORA1
SCHEMBL860142 0.67 ADORA1 (0.37) ADORA1
SCHEMBL29068760 0.67 ADORA1 (0.41) ADORA1
SCHEMBL94835 0.67 PYGB (0.44)
SCHEMBL27777686 0.67 ADORA1 (0.37) ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3688169-A2 GENETIC KNOCKOUTS IN WOOD-LJUNGDAHL MICROORGANISMS Lanzatech, Inc. (US) 2020-08-05 EP disclosed
US-20200239896-A1 GENETIC KNOCKOUTS IN WOOD-LJUNGDAHL MICROORGANISMS LANZATECH, INC. 2020-07-30 US disclosed
WO-2019068011-A2 GENETIC KNOCKOUTS IN WOOD-LJUNGDAHL MICROORGANISMS LANZATECH, INC. (US) 2019-04-04 WO disclosed
US-20190040417-A1 BIOLOGICAL FERMENTATION USING DIHYDROXYACETONE AS A SOURCE OF CARBON KEMBIOTIX LLC (US) 2019-02-07 US disclosed
WO-2017139420-A1 BIOLOGICAL FERMENTATION USING DIHYDROXYACETONE AS A SOURCE OF CARBON KEMBIOTIX LLC (US) 2017-08-17 WO disclosed
US-20170037363-A1 AMMONIA-OXIDIZING NITROSOMONAS EUTROPHA STRAIN D23 AOBIOME LLC (US) 2017-02-09 US disclosed
US-20150240226-A1 NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM BP CORP NORTH AMERICA INC (US) 2015-08-27 US disclosed
US-8962800-B2 Nucleic acids and proteins and methods for making and using them BP CORPORATION NORTH AMERICA INC. (US) 2015-02-24 US disclosed
US-20140242640-A1 Methods of Making Nanotechnological and Macromolecular Biomimetic Structures SUNGUROFF ALEXANDER (US) 2014-08-28 US disclosed
US-20140017725-A1 Methods of Making Nanotechnological and Macromolecular Biomimetic Structures SUNGUROFF ALEXANDER (US) 2014-01-16 US disclosed
US-20100011456-A1 Nucleic Acids and Proteins and Methods for Making and Using Them VERENIUM CORPORATION (US) 2010-01-14 US disclosed
US-20090275104-A1 Bacillus licheniformis chromosone NOVOZYMES A/S (DK) 2009-11-05 US disclosed
US-7494798-B2 Bacillus licheniformis chromosome NOVOZYMES, INC. (US) 2009-02-24 US disclosed
US-20080096253-A1 Artificial ribosome for use as synthesis structure during in vitro translation SUNGUROFF ALEXANDER 2008-04-24 US disclosed
US-20080050774-A1 Computer-based system for monitoring differential expression; host cells NOVOZYMES A/S (DK) 2008-02-28 US disclosed
CN-101082049-A Corynebacterium glutamicum genes encoding metabolic pathway proteins BASF AG (DE) 2007-12-05 CN disclosed
CN-101074441-A Corynebacterium glutamicum genes encoding metabolic pathway proteins BASF AG (DE) 2007-11-21 CN disclosed
US-20060252112-A1 Methods for indentifying compounds that modulate an enzyme involved in biotin metabolism in a pathogenic microorganism SCHECHTER ALAN M 2006-11-09 US disclosed
US-20050260707-A1 Corynebacterium glutamicum genes encoding metabolic pathway proteins BASF AKTIENGESELLSCHAFT (DE) 2005-11-24 US disclosed
WO-2002064794-A2 HERBICIDE TARGET GENES AND METHODS SYNGENTA PARTICIPATIONS AG (CH) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150240226-A1 NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM POLN, POLM, POLI ADORA1 1721/4885ADK 1513/4885
US-20060252112-A1 Methods for indentifying compounds that modulate an enzyme involved in biotin metabolism in a pathogenic microorganism BTD, BLVRB, BPGM ADORA1 2955/4885ADK 836/4885
US-20100011456-A1 Nucleic Acids and Proteins and Methods for Making and Using Them POLN, POLM, POLI ADORA1 1721/4885ADK 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.